Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: radman33 who wrote (751)	5/18/1999 5:05:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 942

Details of today's analyst meeting from Bloomberg: Warner-Lambert Plans to Spend $1.17 Billion on R&D in 1999 news.com New York, May 18 (Bloomberg) -- Warner-Lambert Co., maker of Lipitor, the top-selling cholesterol-reducing drug in the U.S., said it will spend $1.17 billion on research and development this year, up 51 percent from $777 million last year. Warner-Lambert Expects 30% EPS Increase in 1999, 20% in 2000 news.com New York, May 18 (Bloomberg) -- Warner-Lambert Co., maker of Lipitor, the top-selling cholesterol-reducing drug in the U.S., said it expects to increase earnings per share by 30 percent in 1999 from $1.48 last year. The company is expected to earn $1.93 a share in 1999, the average estimate of analysts polled by First Call Corp. Warner- Lambert said at an analysts' meeting in New York that it expects earnings of about $1.92 for the year. The Morris Plains, New Jersey-based company said it expects 20 percent earnings growth in 2000. Sales of Lipitor, which the company said will grow 50 percent to $3.3 billion this year, are helping to fuel the increase in profit. Warner-Lambert Expects 1999 Celexa Sales of $300 Mln in U.S. news.com New York, May 18 (Bloomberg) -- Warner-Lambert Co., maker of Lipitor, the top-selling cholesterol-reducing drug in the U.S., said sales of the antidepressant Celexa could reach $300 million this year in the U.S. The comments were made at an analysts' meeting in New York. Celexa, a drug marketed by Warner-Lambert and Forest Laboratories Inc., was introduced in the U.S. in 1998. The drug has been taking market share away from Eli Lilly & Co.'s Prozac. Celexa could eventually capture 15 to 20 percent of the U.S. market, Warner-Lambert said. Warner-Lambert Plans to Compare Rezulin With Avandia, Actos news.com New York, May 18 (Bloomberg) -- Warner-Lambert Co., maker of Lipitor, the top-selling cholesterol-reducing drug in the U.S., said it plans to do studies comparing its diabetes pill, Rezulin, with two rival drugs expected to win U.S. approval this year. Rezulin, which Warner-Lambert licenses from Japan's Sankyo Co., has been linked to about 38 cases of death and serious liver damage. The drug has been prescribed for more than 1.5 million people since its 1997 introduction. Warner-Lambert Expects Lipitor Sales of $3.3 Bln This Year news.com New York, May 18 (Bloomberg) -- Warner-Lambert Co., maker of Lipitor, the top-selling cholesterol-reducing drug in the U.S., said it expects sales of the drug to increase 50 percent to $3.3 billion in 1999 worldwide and $4 billion in 2000.